Satisfaction and treatment adherence in erectile dysfunction in the medium and long term
Por:
Panach-Navarrete J, Morales-Giraldo A, Ferrandis-Cortés C, García-Morata F, Pastor-Lence JC and Martínez-Jabaloyas JM
Publicada:
1 may 2017
Ahead of Print:
16 nov 2016
Categoría:
Urology
Resumen:
Introduction: The aim of this study was to show the satisfaction and
treatment adherence in erectile dysfunction (ED) in the medium and long
term.
Material and methods: A descriptive, comparative study was conducted in
2 centres through telephone interviews with patients who came for an
initial visit between 2012 and 2014 for ED.
A complete case history review was conducted on the use of and
withdrawal from treatment. For current use, the Erectile Dysfunction
Inventory of Treatment Satisfaction (EDITS) and the Global Assessment
Questionnaire (GAQ) were filled out; for past use, only the GAQ was
filled out.
For the statistical analysis, we employed Fisher's exact test for
comparisons of percentages and the Kruskal-Wallis test to compare means.
Results: The study included 250 patients; 20.8% were prescribed
intraurethral alprostadil (ALP-IU), 17.2% were prescribed intracavernous
alprostadil (ALP-IC), 92.8% were prescribed a first IPD5, and 24.8% were
prescribed at least a second IPD5.
The treatment withdrawal rate was 62.07% for the first IPD5, 41.94% for
the last IPD5, 69.23% for the ALP-IU and 65.11% for the ALP-IC (P=.007).
The main reason for withdrawal for the IPD5 was a lack of response
(32.76% of those who took IPD5). In addition to withdrawal, there were
adverse reactions for ALP-IU and ALP-IC (28.85% and 11.63%,
respectively). The mean duration of use until withdrawal was 4.3 months
for IPD5, 2.2 months for ALP-IU and 5.5 months for ALP-IC (P=.064). The
most favourable GAQ and EDITS scores were observed for IPD5 (EDITS score
of 74). Sildenafil and tadatafil had the longest usage times (mean > 5
months).
Conclusions: The withdrawal rate for treating ED is high, with short
usage times of a few months. A lack of response and adverse reactions
were the main causes for withdrawal. The drugs that provide greater
satisfaction are the IPD5, although there are no significant differences
in the mean usage time between the different types and in aspects such
as the mean usage time to withdrawal or the withdrawal rates. (C) 2016
AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
:
Servicio de Urología, Hospital Clínico Universitario de Valencia, Universitat de València, Valencia, España.
Morales-Giraldo A:
Servicio de Urología, Hospital Clínico Universitario de Valencia, Universitat de València, Valencia, España
:
Servicio de Urología, Hospital Universitario de La Ribera, Alzira, Valencia, España
García-Morata F:
Servicio de Urología, Hospital Clínico Universitario de Valencia, Universitat de València, Valencia, España
:
Servicio de Urología, Hospital Universitario de La Ribera, Alzira, Valencia, España
Martínez-Jabaloyas JM:
Servicio de Urología, Hospital Clínico Universitario de Valencia, Universitat de València, Valencia, España
|